ORGANIZATION

9 EFPIA Companies Reviewed Headcount Planning after Drug Pricing Overhaul: Survey

December 5, 2018
Japan’s drastic drug pricing reform in April has goaded nine EFPIA Japan member companies to give a second thought about their headcount planning, with shocks from narrowed premium pricing coverage introduced for on-patent medicines apparently reverberating on the employment front,…

To read the full story

Related Article

ORGANIZATION

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…